ClinicalTrials.gg
CompletedNCT05027074Updated Feb 11, 2026Results posted

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

A Phase 2 interventional study of MK-2060 and Placebo in End-Stage Renal Disease, End-Stage Kidney Disease and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 120 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.

Enrollment
Largest of 12
506 · median 18
Started
2021
the only one that year
Phase 2
Only one
of the 12
Registered
7th of 12
by date

Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one has the largest enrollment, is the only one that started in 2021, is the only one in phase 2, and was the 7th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is that at least one of the MK-2060 doses is superior to placebo in increasing the time to first occurrence of AVG event.

03

Conditions studied

  • End-Stage Renal Disease
  • End-Stage Kidney Disease
  • Kidney Failure, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current diagnosis of ESRD.
  • Receiving hemodialysis (including hemodiafiltration) ≥3 times per week for a minimum of 3 hours per session via a mature normally functioning, uninfected AVG with at least 75% of the sessions meeting these criteria over the 4 weeks prior to randomization.
  • A female participant is not pregnant or breastfeeding, not a woman of (WOCBP) or is a WOCBP and agrees to follow guidance during the intervention period and for at least 90 days after the last dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Recent history of cancer (\<1 year). Non-melanoma skin cancers are allowed.
  • Mechanical/prosthetic heart valve.
  • Recent hemorrhagic stroke or lacunar stroke (\<1 month).
  • Recent evidence (\<1 month) of bleeding requiring hospitalization or unplanned medical attention, a history (≤2 years) of recurrent bleeding episodes including epistaxis, gastrointestinal (GI) bleeds or genitourinary (GU) bleeds requiring medical treatment or events requiring treatment with blood products.
  • Recent history (\<1 year) of drug or alcohol abuse or dependence.
  • Currently receiving or planning to receive anticoagulants or antiplatelet medications (intradialytic heparin and aspirin are permitted).
  • Planning on receiving a living donor renal transplant within 12 months (participants are permitted to be candidates for deceased donor renal transplants).
  • Planning on receiving an arteriovenous fistula (AVF) placement within 12 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
506 participants (actual)

Study arms

  • Experimental
    MK-2060 20 mg

    MK-2060 20 mg administered via IV infusion during dialysis as a loading dose: QOD during week 1 (3 administrations), then QW after week 1

    Drug: MK-2060

  • Experimental
    MK-2060 6 mg

    MK-2060 6 mg administered via intravenous (IV) infusion during dialysis as a loading dose: Every other day (QOD) during week 1 (3 administrations), then once a week (QW) after week 1

    Drug: MK-2060

  • Placebo comparator
    Placebo

    Placebo (normal saline) administered via IV infusion during dialysis as a loading dose: QOD during week 1 (3 administrations), then once a week after week 1

    Drug: Placebo

Interventions

  • MK-2060 lyophilized powder diluted in normal saline and administered via IV infusion

  • DrugPlacebo

    Normal saline administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Time to First Arteriovenous Graft (AVG) Thrombosis Event

    An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. A blinded independent clinical adjudication committee (CAC) adjudicated AVG thrombosis events. A time-to-event methodology was used to evaluate the results. The incidence rate is presented.

    Time frame: From date of randomization until the date of first occurrence of an AVG thrombosis event, assessed up to approximately 37 months

Secondary outcomes

  1. Time to Each AVG Thrombosis Event (First and Recurrent)

    An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. A blinded independent CAC adjudicated AVG thrombosis events. A time-to-event methodology was used to evaluate the results. The incidence rate is presented.

    Time frame: Up to approximately 37 months

  2. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with one or more AEs is presented.

    Time frame: Up to approximately 40 months

  3. Time to First Event of International Society on Thrombosis (ISTH) Major Bleeding Event or a Clinically Relevant Non-Major Bleeding Event

    Major bleeding events were defined as a having symptomatic presentation and including ≥1 of the following criteria: 1) Fatal bleeding 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intramuscular with compartment syndrome 3) Bleeding causing decrease in hematocrit level of 20 g/L or more or leading to transfusion of ≥2 units of whole blood or red cells. Clinically relevant non-major bleeding events were defined as signs or symptoms of hemorrhage that do not meet criteria for major bleeding events but meet ≥1 of the following criteria: 1) Requiring medical intervention by healthcare professional 2) Leading to hospitalization or increased level of care 3) Prompting face-to-face evaluation by healthcare professional. A time-to-event methodology was used. The incidence rate is presented.

    Time frame: From date of first dose of study intervention until the first ISTH major bleeding event or a clinically relevant non-major bleeding event. assessed up to approximately 40 months

  4. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study intervention due to an AE is presented.

    Time frame: Up to approximately 37 months

07

Results

Posted Nov 17, 2025

Participant flow

Participant flow — Overall Study
MilestoneMK-2060 20 mgMK-2060 6 mgPlacebo
Started171167168
Treated170164168
Completed105113113
Not completed665455
Withdrew: Death474239
Withdrew: Withdrawal by parent/guardian100
Withdrew: Site terminated by sponsor302
Withdrew: Withdrawal by subject13810
Withdrew: Lost to follow-up243
Withdrew: Status not recorded001

Outcome measures

PrimaryTime to First Arteriovenous Graft (AVG) Thrombosis Event

An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. A blinded independent clinical adjudication committee (CAC) adjudicated AVG thrombosis events. A time-to-event methodology was used to evaluate the results. The incidence rate is presented.

Time frame:
From date of randomization until the date of first occurrence of an AVG thrombosis event, assessed up to approximately 37 months
Reported as:
Number · events per 100 person-years
Time to First Arteriovenous Graft (AVG) Thrombosis Event
events per 100 person-yearsMK-2060 20 mgMK-2060 6 mgPlacebo
Time to First Arteriovenous Graft (AVG) Thrombosis Event23.8022.9830.17
Statistical analysis
  • MK-2060 20 mg vs Placebo · Log Rank · p = 0.470 (From log-rank test stratified by region (US, Non-US), previous thrombosis of active AVG (yes, no) and regular aspirin use up to 150 mg daily at baseline (yes, no).) · Hazard ratio (hr): 0.87 · 95% CI 0.60 to 1.26HR based on stratified Cox model with Efron's method of tie handling and with a single treatment covariate, controlling for stratification factors of region, previous thrombosis of active AVG and regular aspirin use up to 150 mg daily at baseline.
  • MK-2060 6 mg vs Placebo · Hazard ratio (hr): 0.83 · 95% CI 0.57 to 1.19HR based on stratified Cox model with Efron's method of tie handling and with a single treatment covariate, controlling for stratification factors of region, previous thrombosis of active AVG and regular aspirin use up to 150 mg daily at baseline.
SecondaryTime to Each AVG Thrombosis Event (First and Recurrent)

An AVG thrombosis event is defined as the sudden occlusion of the participant's AVG requiring thrombectomy/thrombolysis, or clinical evidence of thrombosis with surgical, radiological or pathological conformation of an AVG thrombosis. A blinded independent CAC adjudicated AVG thrombosis events. A time-to-event methodology was used to evaluate the results. The incidence rate is presented.

Time frame:
Up to approximately 37 months
Reported as:
Number · events per 100 person-years
Time to Each AVG Thrombosis Event (First and Recurrent)
events per 100 person-yearsMK-2060 20 mgMK-2060 6 mgPlacebo
Time to Each AVG Thrombosis Event (First and Recurrent)38.9537.8542.97
Statistical analysis
  • MK-2060 20 mg vs Placebo · Hazard ratio (hr): 0.91 · 95% CI 0.68 to 1.21HR based on Andersen-Gill model with stratification factors of region, previous thrombosis of active AVG, and regular aspirin use up to 150 mg daily at baseline as fixed effect.
  • MK-2060 6 mg vs Placebo · Hazard ratio (hr): 0.93 · 95% CI 0.70 to 1.23HR based on Andersen-Gill model with stratification factors of region, previous thrombosis of active AVG, and regular aspirin use up to 150 mg daily at baseline as fixed effect.
SecondaryNumber of Participants Who Experience One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with one or more AEs is presented.

Time frame:
Up to approximately 40 months
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Adverse Events (AEs)
ParticipantsMK-2060 20 mgMK-2060 6 mgPlacebo
Number of Participants Who Experience One or More Adverse Events (AEs)161143155
SecondaryTime to First Event of International Society on Thrombosis (ISTH) Major Bleeding Event or a Clinically Relevant Non-Major Bleeding Event

Major bleeding events were defined as a having symptomatic presentation and including ≥1 of the following criteria: 1) Fatal bleeding 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, intramuscular with compartment syndrome 3) Bleeding causing decrease in hematocrit level of 20 g/L or more or leading to transfusion of ≥2 units of whole blood or red cells. Clinically relevant non-major bleeding events were defined as signs or symptoms of hemorrhage that do not meet criteria for major bleeding events but meet ≥1 of the following criteria: 1) Requiring medical intervention by healthcare professional 2) Leading to hospitalization or increased level of care 3) Prompting face-to-face evaluation by healthcare professional. A time-to-event methodology was used. The incidence rate is presented.

Time frame:
From date of first dose of study intervention until the first ISTH major bleeding event or a clinically relevant non-major bleeding event. assessed up to approximately 40 months
Reported as:
Number · events per 100 person-years
Time to First Event of International Society on Thrombosis (ISTH) Major Bleeding Event or a Clinically Relevant Non-Major Bleeding Event
events per 100 person-yearsMK-2060 20 mgMK-2060 6 mgPlacebo
Time to First Event of International Society on Thrombosis (ISTH) Major Bleeding Event or a Clinically Relevant Non-Major Bleeding Event24.7318.0514.04
Statistical analysis
  • MK-2060 20 mg vs Placebo · Log Rank · p = 0.022 (From log-rank test stratified by region (US, Non-US), previous thrombosis of active AVG (yes, no) and regular aspirin use up to 150 mg daily at baseline (yes, no).) · Hazard ratio (hr): 1.68 · 95% CI 1.07 to 2.62HR based on stratified Cox model with Efron's method of tie handling and with a single treatment covariate, controlling for stratification factors of region, previous thrombosis of active AVG and regular aspirin use up to 150 mg daily at baseline.
  • MK-2060 6 mg vs Placebo · Log Rank · p = 0.311 (From log-rank test stratified by region (US, Non-US), previous thrombosis of active AVG (yes, no) and regular aspirin use up to 150 mg daily at baseline (yes, no).) · Hazard ratio (hr): 1.27 · 95% CI 0.800 to 2.00HR based on stratified Cox model with Efron's method of tie handling and with a single treatment covariate, controlling for stratification factors of region, previous thrombosis of active AVG and regular aspirin use up to 150 mg daily at baseline.
SecondaryNumber of Participants Who Discontinue Study Intervention Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study intervention due to an AE is presented.

Time frame:
Up to approximately 37 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Intervention Due to an AE
ParticipantsMK-2060 20 mgMK-2060 6 mgPlacebo
Number of Participants Who Discontinue Study Intervention Due to an AE473246

Adverse events

Collected over Up to approximately 40 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-2060 20 mg50/171 (29.2%)110/170 (64.7%)111/170 (65.3%)
MK-2060 6 mg43/167 (25.7%)95/164 (57.9%)106/164 (64.6%)
Placebo41/168 (24.4%)112/168 (66.7%)109/168 (64.9%)
Most frequent serious events
Showing 10 of 325
Most frequent serious events
EventMK-2060 20 mgMK-2060 6 mgPlacebo
Arteriovenous graft thrombosisInjury, poisoning and procedural complications13/17019/16419/168
PneumoniaInfections and infestations10/1709/16413/168
HyperkalaemiaMetabolism and nutrition disorders7/1706/16412/168
SepsisInfections and infestations7/1704/16411/168
HypervolaemiaMetabolism and nutrition disorders8/1709/16411/168
Cardiac failure congestiveCardiac disorders10/1701/1645/168
Chest painGeneral disorders3/1709/1642/168
Acute myocardial infarctionCardiac disorders9/1706/1648/168
Acute respiratory failureRespiratory, thoracic and mediastinal disorders6/1708/1645/168
COVID-19Infections and infestations7/1703/1646/168
Most frequent other events
Showing 10 of 24
Most frequent other events
EventMK-2060 20 mgMK-2060 6 mgPlacebo
Arteriovenous graft thrombosisInjury, poisoning and procedural complications29/17035/16443/168
Arteriovenous graft site stenosisInjury, poisoning and procedural complications22/17023/16423/168
DiarrhoeaGastrointestinal disorders11/17020/1649/168
COVID-19Infections and infestations13/17010/16418/168
HypertensionVascular disorders17/1709/16410/168
Arteriovenous graft site haemorrhageInjury, poisoning and procedural complications9/17016/1647/168
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1708/16416/168
HypotensionVascular disorders12/1707/16415/168
FallInjury, poisoning and procedural complications15/17011/1649/168
Pain in extremityMusculoskeletal and connective tissue disorders15/1706/1649/168

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-2060 20 mgMK-2060 6 mgPlaceboTotal
Mean62.2 ± 13.558.8 ± 12.860.5 ± 14.860.5 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)MK-2060 20 mgMK-2060 6 mgPlaceboTotal
Female978183261
Male748685245
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-2060 20 mgMK-2060 6 mgPlaceboTotal
Hispanic or Latino776765209
Not Hispanic or Latino9198100289
Unknown or Not Reported3238
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-2060 20 mgMK-2060 6 mgPlaceboTotal
American Indian or Alaska Native2114
Asian66416
Native Hawaiian or Other Pacific Islander0022
Black or African American637367203
White998694279
More than one race1102
Unknown or Not Reported0000
Region
Region(Participants)MK-2060 20 mgMK-2060 6 mgPlaceboTotal
US118117118353
non-US535050153
Previous Thrombosis of Active Arteriovenous Graft (AVG)
Previous Thrombosis of Active Arteriovenous Graft (AVG)(Participants)MK-2060 20 mgMK-2060 6 mgPlaceboTotal
Yes383540113
No133132128393
Regular Aspirin Use up to 150 mg Daily at Baseline
Regular Aspirin Use up to 150 mg Daily at Baseline(Participants)MK-2060 20 mgMK-2060 6 mgPlaceboTotal
Yes726967208
No9998101298
08

Study locations

120 sites
  • Nephrology Consultants ( Site 0681)
    Huntsville, Alabama 35805, United States
  • AKDHC MEDICAL RESEARCH SERVICES, LLC-Maryvale ( Site 0723)
    Phoenix, Arizona 85035, United States
  • AKDHC Medical Research Services, LLC ( Site 0629)
    Tucson, Arizona 85741, United States
  • DaVita Anaheim West Dialysis-Davita Anaheim West Dialysis - Ismail ( Site 0562)
    Anaheim, California 92801, United States
  • DaVita Bakersfield Oak Street Dialysis-Clinical Research ( Site 0547)
    Bakersfield, California 93304, United States
  • Fresenius Kidney Care Bakersfield Northeast ( Site 0647)
    Bakersfield, California 93306, United States
  • Fresenius Kidney Care Meadows Field ( Site 0618)
    Bakersfield, California 93308, United States
  • California Institute Of Renal Research ( Site 0660)
    Chula Vista, California 91910, United States
  • Citrus Dialysis Center ( Site 0609)
    Covina, California 91723, United States
  • California Institute Of Renal Research ( Site 0679)
    El Centro, California 92243, United States
  • California Institute of Renal Research ( Site 0566)
    Escondido, California 92025, United States
  • Fresenius Kidney Care Newhope Fountain Valley ( Site 0617)
    Fountain Valley, California 92708, United States
  • DaVita Glendale Heights ( Site 0604)
    Glendale, California 91201, United States
  • DaVita West Glendale Dialysis ( Site 0579)
    Glendale, California 91205, United States
  • DaVita North Glendale ( Site 0552)
    Glendale, California 91206, United States
  • California Institute of Renal Research - La Mesa ( Site 0682)
    La Mesa, California 91941, United States
  • La Puente Dialysis Center ( Site 0610)
    La Puente, California 91744, United States
  • Academic Medical Research Institute ( Site 0533)
    Los Angeles, California 90022, United States
  • DaVita Kidney Center - East LA Plaza Dialysis ( Site 0548)
    Los Angeles, California 90033, United States
  • DaVita Crescent Heights Dialysis Center ( Site 0574)
    Los Angeles, California 90048, United States
  • North America Research Institute ( Site 0587)
    Lynwood, California 90262, United States
  • North America Research Institute ( Site 0612)
    Lynwood, California 90262, United States
  • Valley Renal Medical Group Research-Clinical Research ( Site 0651)
    Northridge, California 91343, United States
  • California Institute of Renal Research - Kearny Mesa ( Site 0678)
    San Diego, California 92111, United States
  • North America Research Institute ( Site 0611)
    San Dimas, California 91773, United States
  • DaVita Van Nuys Dialysis ( Site 0538)
    Van Nuys, California 91405, United States
  • Desert Cities Diaylsis-Clinical Research ( Site 0615)
    Victorville, California 92392, United States
  • DaVita Clinical Research - Hartford ( Site 0507)
    Hartford, Connecticut 06112, United States
  • DaVita Clinical Research - Middlebury ( Site 0511)
    Middlebury, Connecticut 06762, United States
  • Research Physicians Network Alliance ( Site 0563)
    Boca Raton, Florida 33431, United States
  • Horizon Research Group ( Site 0578)
    Coral Gables, Florida 33134, United States
  • Horizon Research Group ( Site 0581)
    Coral Gables, Florida 33134, United States
  • Elixia at Florida Kidney Physicians - Southeast ( Site 0602)
    Fort Lauderdale, Florida 33308, United States
  • South Florida Research Institute ( Site 0656)
    Fort Lauderdale, Florida 33313, United States
  • Elixia Clinical Research Collaborative (CRC) - Southeast Florida ( Site 0728)
    Hollywood, Florida 33020, United States
  • Pines Clinical Research ( Site 0605)
    Hollywood, Florida 33024, United States
  • Floridian Clinical Research, LLC ( Site 0684)
    Miami Lakes, Florida 33016, United States
  • Omega Research Orlando ( Site 0645)
    Orlando, Florida 32808, United States
  • Genesis Clinical Research, LLC ( Site 0585)
    Tampa, Florida 33603, United States
  • Genesis Clinical Research, LLC ( Site 0594)
    Tampa, Florida 33603, United States
  • Genesis Clinical Research, LLC ( Site 0680)
    Tampa, Florida 33603, United States
  • DaVita Clinical Research - Columbus ( Site 0532)
    Columbus, Georgia 31904, United States
  • Renal Physicians of Georgia ( Site 0577)
    Macon, Georgia 31217, United States
  • DaVita East Georgia Dialysis Unit ( Site 0536)
    Statesboro, Georgia 30458, United States
  • University of Chicago Medical Center-Medicine - Section of Nephrology ( Site 0595)
    Chicago, Illinois 60637, United States
  • Nephrology Specialists - Merrillville ( Site 0537)
    Merrillville, Indiana 46410, United States
  • Nephrology Specialists - Michigan City ( Site 0541)
    Michigan City, Indiana 46360, United States
  • Capital Nephrology ( Site 0596)
    Greenbelt, Maryland 20770, United States
  • Henry Ford Hospital-Nephrology and Hypertension ( Site 0694)
    Detroit, Michigan 48202, United States
  • St. Clair Nephrology Research - Roseville ( Site 0597)
    Roseville, Michigan 48066, United States
  • DaVita Clinical Research ( Site 0502)
    Minneapolis, Minnesota 55404, United States
  • Fresenius Kidney Care Brookhaven ( Site 0693)
    Brookhaven, Mississippi 39601, United States
  • Clinical Research Consultants, LLC ( Site 0542)
    Kansas City, Missouri 64111, United States
  • Somnos Clinical Research ( Site 0669)
    Lincoln, Nebraska 68505, United States
  • DaVita Five Star Dialysis Center ( Site 0509)
    Las Vegas, Nevada 89128, United States
  • Renal Medicine Associates ( Site 0690)
    Albuquerque, New Mexico 87109, United States
  • Capital District Renal Physicians ( Site 0633)
    Albany, New York 12209, United States
  • Ridgewood Dialysis Center ( Site 0725)
    Ridgewood, New York 11385, United States
  • Albert Einstein College of Medicine-Department of Medicine-Nephrology Einstein ( Site 0628)
    The Bronx, New York 10461, United States
  • DaVita Clinical Researh ( Site 0501)
    The Bronx, New York 10461, United States
  • Fresenius Kidney Care - Charlotte ( Site 0686)
    Charlotte, North Carolina 28208, United States
  • Durham Nephrology Associates ( Site 0655)
    Durham, North Carolina 27704, United States
  • East Carolina University-Department of Nephrology & Hypertension ( Site 0663)
    Greenville, North Carolina 27834, United States
  • Kidney and Hypertension Center ( Site 0571)
    Roseburg, Oregon 97471, United States
  • Northeast Clinical Research Center ( Site 0653)
    Bethlehem, Pennsylvania 18017, United States
  • Elixia at Clinical Renal Associates ( Site 0677)
    Upland, Pennsylvania 19013, United States
  • South Carolina Nephrology & Hypertension Center-Research ( Site 0672)
    Orangeburg, South Carolina 29118, United States
  • Knoxville Kidney Center ( Site 0689)
    Knoxville, Tennessee 37923, United States
  • Renal Disease Research Institute ( Site 0621)
    Dallas, Texas 75235, United States
  • DaVita Clinical Research - El Paso ( Site 0505)
    El Paso, Texas 79925, United States
  • DaVita Clinical Research - Houston ( Site 0508)
    Houston, Texas 77004, United States
  • Clinical Research Strategies ( Site 0625)
    Houston, Texas 77090, United States
  • Southwest Houston Research ( Site 0649)
    Houston, Texas 77099, United States
  • Texas Institute for Kidney and Endocrine Disorders ( Site 0626)
    Lufkin, Texas 75904, United States
  • Gamma Medical Research ( Site 0688)
    McAllen, Texas 78503, United States
  • DaVita Clinical Research - Norfolk ( Site 0513)
    Norfolk, Virginia 23502, United States
  • DaVita Clinical Research - Milwaukee ( Site 0512)
    Wauwatosa, Wisconsin 53226, United States
  • FME Mansilla ( Site 0007)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1425BPM, Argentina
  • Fresenius Medical Care - Moron ( Site 0008)
    Morón, Buenos Aires B1708DPO, Argentina
  • Fresenius Medical Care - San Fernando ( Site 0013)
    San Fernando, Buenos Aires 1646, Argentina
  • CEREHA ( Site 0004)
    Sarandí, Buenos Aires B1872JBA, Argentina
  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0010)
    Buenos Aires, Buenos Aires F.D. C1431FWO, Argentina
  • Fresenius Medical Care Ciudad Evita ( Site 0006)
    Buenos Aires, B1778IFA, Argentina
  • Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0001)
    Santa Fe, 3000, Argentina
  • Western Health-Sunshine & Footscray Hospitals-Renal Services ( Site 0054)
    St Albans, Victoria 3021, Australia
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site
    São José do Rio Preto, São Paulo 15090000, Brazil
  • Fresenius Clinical Trials Perdizes ( Site 0101)
    São Paulo, São Paulo 05024-030, Brazil
  • Hospital do Rim e Hipertensão ( Site 0106)
    São Paulo, 04038-002, Brazil
  • Multiprofile Hospital for Active Treatment - "Dr. Cherven Bryag"-Department of dialysis treatment (
    Cherven Bryag, Lovech 5980, Bulgaria
  • MHAT Dobrich-Department for dialysis treatment ( Site 0161)
    Dobrich, 9300, Bulgaria
  • First Dialysis Services Bulgaria ( Site 0158)
    Montana, 3400, Bulgaria
  • UMBAL Plovdiv AD-Deparment of Hemodialysis ( Site 0162)
    Plovdiv, 4003, Bulgaria
  • Hemomed ( Site 0159)
    Sofia, 1618, Bulgaria
  • University Of Alberta Hospital ( Site 1001)
    Edmonton, Alberta T6G 2B7, Canada
  • Toronto General Hospital ( Site 1002)
    Toronto, Ontario M5G 2C4, Canada
  • Fresenius Medical Care - Dialyzační středisko ( Site 0254)
    Prague, Praha 4 142 00, Czechia
  • Dialýza ( Site 0256)
    Beroun, 266 01, Czechia
  • Fresenius Medical Care ( Site 0253)
    Pardubice, 532 03, Czechia
  • DaVita Clinical Research Germany GmbH ( Site 0901)
    Düsseldorf, North Rhine-Westphalia 40210, Germany
  • ATTIKON GENERAL UNIVERSITY HOSPITAL-2nd Dep. of Int. Medicine. Research Unit & Diabetes Center ( Sit
    Chaïdári, Attica 124 62, Greece

Showing the first 100 of 120 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2024, 37 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 37 months is above that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2021
First posted
Aug 30, 2021
StartActual
Sep 17, 2021
Primary completionActual
Oct 30, 2024
CompletionActual
Feb 13, 2025
Results first posted
Nov 17, 2025
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05027074
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Sep 17, 2021
Primary completion
Oct 30, 2024
Completion
Feb 13, 2025
Results posted
Nov 17, 2025
Last update
Feb 11, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-2060

Start the discussion